JPRN-jRCT2011210010进行中（未招募）未知
38-501 : BRAFTOVI/MEKTOVI Combination Therapy Specified Drug Use Survey (Radically unresectable malignant melanoma with a BRAF gene mutation)
Kuro Toshihiko0 个研究点目标入组 150 人开始时间: 2021年5月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •All patients with radically unresectable malignant melanoma with a BRAF gene mutation for whom BRAFTOVI/MEKTOVI Combination Therapy is performed
排除标准
- •patients who have not received BRAFTOVI and/or MEKTOVI
研究者
相似试验
进行中（未招募）
不适用
38-502:BRAFTOVI/MEKTOVI Combination Therapy Specified Drug Use Survey(CRC)unresectable advanced or recurrent BRAF-mutant colorectal cancerJPRN-jRCT2011210012Kuro Toshihiko220
进行中（未招募）
1 期
Efficacy of trametinib and dabrafenib associated with radioactive iodine for the treatment of refractory metastatic differentiated thyroid cancerEUCTR2017-000742-21-FRGustave Roussy
已完成
不适用
Vicriviroc (SCH 417690) in the Combined Treatment with an Optimized Antiretroviral Regimen in Subjects previously treated (Study VICTOR-E2)PER-055-05SCHERING PLOUGH RESEARCH INSTITUTE,
已完成
不适用
Vicriviroc (SCH 417690) in the Combined Treatment with an Optimized Antiretroviral Regimen in Subjects with Previous Antiretroviral Therapy (Study VICTOR-E1)PER-054-05SCHERING PLOUGH RESEARCH INSTITUTE,
进行中（未招募）
1 期
Vicriviroc (SCH 417690) in Combination Treatment with Optimized ART Regimen in Experienced Subjects (VICTOR-E1) - VICTOR-E1HIV infection (R5-tropism only) with previous therapyLevel: LLTClassification code 10200172EUCTR2005-001057-21-PTSchering-Plough Research Institute